Clinical trials: Adaptive Radiotherapy
Non-small Cell Lung Cancer
MR-Linac Guided Adaptive FSRT for Brain Metastases From Non-small Cell Lung Cancer
This Phase II study is to determine the efficacy and safety of MR-Linac Guided Adaptive fractionated stereotactic radiotherapy (FSRT) in patients with brain metastases in non-small cell lung cancer.
- Trial name
- NCT04946019
- Testing
- Unity-based MR-Linac guided FSRT
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Small Cell Lung Cancer
Pilot Project of Adaptive Thoracic Radiotherapy for Small Cell Lung Cancer
This study is intended to assess the feasibility of adjusting a radiation plan during its course to accommodate for a shrinking tumor target.
- Trial name
- NCT01426841
- Testing
- Adaptive Radiation
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- AHS Cancer Control Alberta
Lymph Node Oligometastases
Adaptive Fractionation in Online Adaptive Stereotactic Radiotherapy for Abdominopelvic Lymph Node Oligometastases
Oligometastases, a state of cancer with up to five metastases, was traditionally treated with systemic treatments like chemotherapy.
- Trial name
- STEAL-3 (NCT07415356)
- Testing
- Online-Adaptive SBRT
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- Joost J. M. E. Nuyttens
Locally Advanced Rectal Cancer (LARC)
Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer
Standard treatment for patients with proficient mismatch repair (pMMR) / microsatellite stable (MSS) locally advanced rectal cancer (LARC) consists primarily of neoadjuvant chemoradiotherapy followed by radical surgery.
- Trial name
- NCT07581626
- Testing
- SCRT+targeted therapy+immunotherapy+chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Malignant Prostate Neoplasm
Daily Adaptive Post-Prostatectomy With Stereotactic Ablative Radiotherapy in Patients With Prostate Cancer
This clinical trial evaluates the feasibility, safety, and tolerability of stereotactic ablative radiotherapy (SABR) using daily adaptive radiation techniques to the prostate fossa and/or pelvic lymph nodes in patients with…
- Trial name
- DAPPER (NCT05830838)
- Testing
- Computed Tomography, Image-Guided Adaptive Radiation Therapy, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
The purpose of this study is to examine the safety and tolerability of treatment with concurrent Sacituzumab Govitecan (SG) and adaptive radiation therapy.
- Trial name
- NCT05833867
- Testing
- Sacituzumab govitecan, Adaptive Radiotherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Shilpa Gupta, MD
Prostate Adenocarcinoma
Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer
You have been asked to consider participating in the study because you have a cancer of the prostate, which is to be treated with external beam radiation.
- Trial name
- 2STAR (NCT02031328)
- Testing
- Stereotactic Ablative Radiation
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Cervical Cancer
Hypofractionated Whole Pelvic Chemoradiotherapy With iRex Optimization in Cervical Cancer
This study is a randomized controlled trial designed to compare hypofractionated whole pelvic radiotherapy with conventional radiotherapy in patients with cervical cancer undergoing concurrent chemoradiotherapy.
- Trial name
- HYPOCx-iRex (NCT07605507)
- Testing
- Hypofractionated Radiotherapy, Conventional Radiotherapy, Concurrent chemotherapy once a week
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Siriraj Hospital
Genitourinary System Carcinoma, Malignant Pelvic Neoplasm
Pilot Investigation of Dual Energy CT Imaging on an Online Adaptive Radiation Therapy System
This study is being done to see if researchers can find a better way to image a patient's tumor during radiation treatment.
- Trial name
- NCT07219134
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Michigan Rogel Cancer Center
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Combination Therapy for the Treatment of Diffuse Midline Gliomas
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs).
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant
- Trial name
- PNOC022 (NCT05009992)
- Testing
- ONC201, Radiation Therapy, Paxalisib
- Where
- 32 sites in United States, Australia and 4 more
- Volunteers
- 360 people
- Sponsor
- University of California, San Francisco
Prostate Cancer, Bladder Cancer
A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer
Radical radiation therapy for prostate cancer is a common treatment that has shown to improve clinical outcomes in a post-operative setting.
- Trial name
- ARTGU (NCT03909893)
- Testing
- Adaptive Radiation Therapy
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Hepatocellular Carcinoma (HCC)
Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma
This study evaluates whether Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) improves overall survival compared with best supportive care (BSC).
- Trial name
- PULSAR-HCC (NCT07895732)
- Testing
- Best Supportive Care (BSC), Personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR)
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer, Adaptive Radiotherapy
Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer
In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany.
- Conditions
- Prostate Cancer, Adaptive Radiotherapy, Quality of Life
- Trial name
- ultraHART (NCT06355050)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Jena University Hospital
Lung Cancer
4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy
To develop and investigate a novel radiotherapy technique for preserving lung function based on a map of lung function.
- Trial name
- NCT01034514
- Testing
- Real-time Position Management system, Discovery ST multislice PET/CT scanner, Infinia Hawkeye SPECT/CT gamma camera
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Billy W. Loo Jr.
Small Cell Lung Cancer Extensive Stage, Brain Metastases
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.
- Conditions
- Small Cell Lung Cancer Extensive Stage, Brain Metastases, Solid Tumor, Adult, Thoracic Cancer
- Trial name
- PRISM (NCT07139990)
- Testing
- Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort C: Sarcoma Pre-Operative PULSAR
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Texas Southwestern Medical Center
Stage III Non-small Cell Lung Cancer
Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer
This is a prospective multi-center randomized clinical trial designed to demonstrate that daily online adaptive radiotherapy with concomitant chemotherapy for stage III non-small cell lung cancer (NSCLC) will result in decreased…
- Trial name
- ARTIA-Lung (NCT05488626)
- Testing
- Adaptive Radiotherapy, Non-Adaptive Radiotherapy, Chemotherapy
- Where
- United States
- Sponsor
- Varian, a Siemens Healthineers Company
Pancreatic Cancer
MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC
The MASPAC trial investigates the added benefit of MR-guided adaptive SBRT of the primary tumor embedded between standard chemotherapy cycles for pain control and prevention of pain in patients with metastatic PDAC (mPDAC).
- Trial name
- MASPAC (NCT05114213)
- Testing
- SBRT, SOC chemotherapy
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 9 people
- Sponsor
- Ludwig-Maximilians - University of Munich
NSCLC (Advanced Non-small Cell Lung Cancer), Adaptive Radiotherapy
Efficiency of Contemporary Off-line Adaptive Radiotherapy for Lung Cancer
Locally advanced non-small cell lung cancer (LA-NSCLC) patients could benefit in overall and progression-free survival from regular dosimetric treatment plan adaptations during radiotherapy.
- Trial name
- ECLAIR (NCT07259447)
- Testing
- CBCT-based adaptive radiotherapy
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
NSCLC, Sintilimab
The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
To evaluate the Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
- Conditions
- NSCLC, Sintilimab, Adaptive Radiotherapy
- Trial name
- NCT07138755
- Testing
- Experimental
- Where
- 4 sites in China
- Volunteers
- 35 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer
This randomized phase II trial studies how well positron emission tomography (PET)/computed tomography (CT)-guided radiation therapy works compared to standard radiation therapy in treating patients with stage III non-small cell…
- Conditions
- Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT01507428
- Testing
- 18F-Fluoromisonidazole, Carboplatin, Computed Tomography
- Where
- 31 sites in United States, Canada
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)